Introduction
Listeria monocytogenes (Lm) is a Gram-positive facultative intracellular pathogen that causes listeriosis (1) . Upon invading a host cell, Lm can escape from the phagolysosome by producing a pore-forming protein listeriolysin O (LLO), which lyses the vesicular membrane, allowing Lm to enter the cytoplasm, where it replicates and spreads to adjacent cells mediated by the mobility of actin-polymerizing protein (ActA) (2) . In the cytoplasm, Lm-secreted proteins are degraded by the proteasome and processed into peptides that associate with MHC class I molecules in the endoplasmic reticulum (3) . This unique characteristic makes it an attractive cancer vaccine vector in that Lm-expressed tumor antigens can be presented with MHC class I molecules to activate tumor-specific cytotoxic T lymphocytes (CTL). Attenuated Lm strains have been generated and developed as cancer vaccine vectors delivering tumor antigens or tumorassociated antigens (TAA) as immunogens to treat various types of cancer (4) (5) (6) (7) (8) (9) (10) .
HPV infection is associated with most cervical cancer, and HPV strain 16 (HPV-16) is detected in about half of cervical cancer cases worldwide (11) . Constitutive expression of HPV-16 E6 and E7 viral proteins in infected cells disrupts the cell cycle and induces malignant proliferation (12) . with plasmid pAM401-hly expressing LLO, it regains hemolytic activity. Bacteria were cultured in brain-heart infusion medium plus streptomycin (100 µg/ml) with or without D-alanine (100 µg/ml).
Materials and methods

Mice
Reagents
Fluorescence conjugated anti-mouse antibodies CD4-PerCP-Cy5.5 (GK1.5) and CD8-Brilliant 
Statistics
The data were analyzed using the nonparametric Mann-Whitney test. Significance was determined at P < 0.05.
Results
LmddA-LLO-E7 induces regression of established TC-1 tumors accompanied by a decrease in Treg frequency
It was reported previously that a Lm-based vaccine, Lm-LLO-E7, which comprises a fusion protein of LLO-E7 and PrfA expressed episomally in a prfA negative strain of Listeria XFL-7, induced complete regression of established TC-1 tumors (14) . Here we investigated the antitumor activity of another highly attenuated Lm-based vaccine, LmddA-LLO-E7, which produces the fusion protein LLO-E7 by a plasmid in a dal, dat, and actA mutated Lm strain (17) .
LmddA-LLO-E7 is safer and even more attenuated compared to Lm-LLO-E7, since the chloramphenicol resistance gene and PrfA have been removed from the plasmid. We found that similar to Lm-LLO-E7 (14), LmddA-LLO-E7 significantly inhibited the growth of established TC-1 tumors (Fig. 1, A Except for one mouse that relapsed and died at 3 months, mice that showed tumor regression (33% of total animals) survived at least 6 months without relapse ( Initially, we suspected that the decrease of Treg frequency was mediated by the truncated LLO.
However, Lm-E7 did not express truncated LLO but was able to decrease Treg frequency (Fig. 1, D-H). This observation suggests that Lm might be able to decrease Treg frequency. Indeed, both LmddA, the vector control for LmddA-LLO-E7, and 10403S, a wild-type Lm strain and the vector control for Lm-E7, significantly decreased Treg frequency in spleens and more so in tumors (Fig. 2) . (Fig. 5A) . In contrast, the number of CD4 + FoxP3 + T cells was not changed significantly after either LmddA or LmddA-LLO infection (Fig 5A) . The administration of LmddA-LLO resulted in a significant decrease of Treg proportion compared to that in PBS control (Fig. 5, B-D) . We also examined the cell proliferation marker Ki-67 in these cells. (Fig. 6, A-C) , and prolonged survival of about 20% of the mice (Fig.   6C ). In contrast, addition of LmddA failed to augment Lm-E7-induced antitumor activity ( Supplementary Fig. S3 ), indicating that endogenous LLO produced by the LmddA vector is not sufficient to enhance antitumor efficacy of the Lm-E7 vaccine. As expected, CD4 
Adoptive transfer of Tregs compromises the antitumor efficacy of LmddA-LLO-E7 against established TC-1 tumors
LmddA-LLO-E7 did not significantly change Treg numbers, although it decreased Treg frequency ( Fig. 1, D-H (Fig. 7, A and B) . However, in mice given Tregs, LmddA-LLO-E7 was unable to significantly inhibit TC-1 tumor growth (Fig. 7, A and B). Mice receiving Tregs showed a slight increase of Treg number in the spleens but higher increase in tumors (Fig. 7, F and G) . On the other hand, mice that received Tregs had fewer (Fig 7, F and G) . These together resulted in the increase of Treg frequency in the Treg-recipient mice (Fig. 7, C 
-E).
Discussion
It is well-known that tumor antigen-specific CTLs play dominant roles in killing tumor cells, and Lm, an intracellular bacteria, can deliver antigens associated with MHC class I molecules to activate CTLs. However, it is unclear why two Lm-based vaccines, Lm-LLO-E7 and Lm-E7, induced similar levels of HPV E7-specific CTLs in the spleens but exhibited distinct antitumor activity, with the former inducing a much stronger antitumor effect (Fig. 1, A-C, Fig. S1, Fig. S2 and (14)). CD8 + T cells are known to participate in killing tumor cells, as their depletion abrogated Lm-LLO-E7-induced tumor regression (14) . It is also clear that a certain level of tumor antigen-specific CTLs is necessary for killing tumor cells, as LmddA-LLO, which lacks E7 expression, was unable to significantly inhibit TC-1 tumor growth (Fig. 1, A-C and Fig. S1 ).
It has been proposed that Lm-E7 induced an increase of Tregs to suppress the host immune response, thus compromising host antitumor immunity (15) . However, we found that both Lm-E7 and LmddA-LLO-E7 decreased Treg frequency in a TC-1 tumor model compared to that in tumor-bearing mice treated with PBS control (Fig. 1, D-H) . Furthermore, we found that neither Lm-E7 nor LmddA-LLO-E7 significantly increased the total number of Tregs in TC-1 tumors after vaccination (Fig. 3) .
In fact, we found that a major difference in vaccine efficacy between LmddA-LLO-E7 and Lm-E7 is that the former was able to induce a marked increase in CD4 (Fig. 3) . This explains how LmddA-LLO-E7 decreased Treg percentage to a greater degree than did Lm-E7 (Fig. 1, D-H) . We observed that the Lm vector alone was sufficient to increase CD4 (Fig. 6) . As a control, LmddA (without the LLO plasmid) in combination with Lm-E7 did not show this effect (Fig S3) , implying that the truncated LLO was necessary. Our data indicate that the LmddA-LLO-E7-induced decrease in Treg frequency is the consequence of an increase in the numbers of CD4 
